VR Logo

Annovis Bio Inc. (ANVS) download report


Healthcare | Biotechnology & Pharma Research

Annovis Bio Inc. (ANVS) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration.

IPO Date: 12-Feb-2010

Founder, CEO, Pres & Exec. Director: Dr. Maria L. Maccecchini Ph.D.

Chief Financial Officer: Mr. Jeffrey B. McGroarty CPA

Listing: NYSE: ANVS

Country: United States

Headquarters: Berwyn, PA

Website: https://www.annovisbio.com

Key Facts

Market cap: $93.72 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-17.18 Mln

Cash: $42.67 Mln

Total Debt: $0.00 Mln

Insider's Holding: 30.94%

Liquidity: Low

52 Week range: $8.39 - 132.00

Shares outstanding: 8,163,920

10 Years Aggregate:

  • CFO: $-16.09 Mln
  • EBITDA: $-14,494.78 Mln
  • Net Profit: $-14,503.31 Mln

Stock Performance

Time Period Annovis Bio (ANVS) S&P BSE Sensex S&P Small-Cap 600
YTD-31.34-9.18-18.78
1 month19.15-4.78-8.00
3 months-9.59-9.66-13.65
1 Year-85.900.81-17.19
3 Years--10.336.10
5 Years--11.345.87
10 Years--11.749.84
As on 01-Jul-2022
Year Annovis Bio (ANVS) S&P Small-Cap 600 S&P BSE Sensex
2021133.1625.2721.99